drugset / Trial / NCT05269121

Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

NCT05269121 ↗

Phase 1/2 Withdrawn Adaptive Phage Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will test the feasibility of a regimen of intraoperative (IO) and intravenous (IV) PhageBank™ bacteriophage therapy in conjunction with a DAIR procedure to cure chronic prosthetic joint infection (PJI) without replacement of the prosthesis.

Timeline

Start
2022-09
Primary completion
2023-11
Completion
2024-11

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject PhageBank™ Unknown — Intravenous